# Adjunctive Oral KET-AD Capsules in Treatment Resistant Bipolar Depression

> **NCT07644767** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Neurocentrx Pharma Pty Ltd** · enrollment: 160 (estimated)

## Conditions studied

- Treatment Resistant Bipolar Depression

## Interventions

- **DRUG:** KET-AD
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT07644767
- **Lead sponsor:** Neurocentrx Pharma Pty Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-10-30
- **Primary completion:** 2028-01-30
- **Final completion:** 2028-06
- **Target enrollment:** 160 (ESTIMATED)
- **Last updated:** 2026-06-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07644767

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07644767, "Adjunctive Oral KET-AD Capsules in Treatment Resistant Bipolar Depression". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07644767. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*